Landmark trial
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial
Ball D, Mai GT, Vinod S, et al. · TROG
DoseLab summary
Randomized phase 3 trial comparing SABR with conventional radiotherapy for peripheral stage I NSCLC. Citation as given in the eviQ reference list; not yet checked against the journal.
Why this is useful
Phase 3 trial of SABR versus standard radiotherapy for stage I NSCLC; source of several three-fraction values in DoseLab's table.
Reference details
- Title
- Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial
- Authors / organization
- Ball D, Mai GT, Vinod S, et al. · TROG
- Publication / protocol
- Lancet Oncol. 2019;20(4):494–503
- Version
- Pending verification
- Year
- 2019
- DOI
- Pending verification
- Disease sites
- Lung
- Topics
- SBRT, Landmark trial, TROG, Peripheral tumors
- Fractionation context
- SABR: 54 Gy/3 fx or 48 Gy/4 fx vs conventional
- Last reviewed by DoseLab
- Pending verification